{
    "nctId": "NCT00004092",
    "briefTitle": "Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer",
    "officialTitle": "Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 72,
    "primaryOutcomeMeasure": "Five-Year Relapse-free Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically proven high-risk primary breast cancer with less than 60% chance of progression-free survival of 3 years from diagnosis\n\n  * Stage II with at least 10 positive axillary nodes OR\n  * Stage IIIA or IIIB\n* No histologically proven bone marrow metastasis\n* No CNS metastasis\n* Hormone receptor status:\n\n  * Hormone receptor status known\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* Physiological age 60 or under\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* Karnofsky 80-100%\n\nLife expectancy:\n\n* See Disease Characteristics\n\nHematopoietic:\n\n* Neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin no greater than 1.5 mg/dL\n* SGOT or SGPT no greater than 2 times upper limit of normal\n* Hepatitis B antigen negative\n\nRenal:\n\n* Creatinine no greater than 1.2 mg/dL\n* Creatinine clearance at least 70 mL/min\n* No prior hemorrhagic cystitis\n\nCardiovascular:\n\n* Ejection fraction at least 55% by MUGA\n* No prior significant valvular heart disease or arrhythmia\n\nPulmonary:\n\n* FEV_1 at least 60% of predicted\n* pO_2 at least 85 mm Hg on room air\n* pCO_2 at least 43 mm Hg on room air\n* DLCO at least 60% lower limit of predicted\n\nOther:\n\n* No other prior malignancy except squamous cell or basal cell skin cancer or stage I or carcinoma in situ of the cervix\n* No CNS dysfunction that would preclude compliance\n* HIV negative\n* No sensitivity to E. coli-derived products\n* Not pregnant\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* At least 4 weeks since prior chemotherapy\n* No prior doxorubicin of total dose exceeding 240 mg/m\\^2\n* No prior paclitaxel of total dose of at least 750 mg/m\\^2\n* No more than 12 months since prior conventional-dose adjuvant chemotherapy\n\nEndocrine therapy:\n\n* At least 4 weeks since prior hormonal therapy\n\nRadiotherapy:\n\n* At least 4 weeks since prior radiotherapy\n* No prior radiation to the left chest wall\n\nSurgery:\n\n* Not specified",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT"
}